Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety

INTRODUCTION: The tyrosine kinase inhibitors regorafenib and cabozantinib remain the mainstay in second-line treatment of advanced hepatocellular carcinoma (HCC). There is currently no clear evidence of superiority in efficacy or safety to guide choice between the two treatments. METHODS: We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Merle, Philippe, Kudo, Masatoshi, Krotneva, Stanimira, Ozgurdal, Kirhan, Su, Yun, Proskorovsky, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267565/
https://www.ncbi.nlm.nih.gov/pubmed/37325487
http://dx.doi.org/10.1159/000527403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267565/
https://www.ncbi.nlm.nih.gov/pubmed/37325487
http://dx.doi.org/10.1159/000527403

Ejemplares similares